Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets ▪ This is OBT’s third major pharma collaboration within the past 12 months and reflects strong validation of the OGAP®-Verify platform's potential to drive oncology innovation ▪ OBT to receive an upfront payment and may be eligible to receive milestone payments, as well as royalties on net sales
https://oxford-biotherapeutics.lon1.cdn.digitaloceanspaces.com/OBT-BMS-2026-04-09.pdf
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.